Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Summary

Prospective national multicenter open label phase II Remodel WM3 trial

Timeline

Start

2017-03-07

Primary completion

2020-08-31

Completion

2023-04-13

Outcome

Met primary endpoint

paper The primary endpoint was achieved with a median PFS of 25.4 months (95% CI, 15.7 to 29.0). PMID 39499299 ↗

Publications

• Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahe B, Morel P, Aurran T, Tournilhac O, Lepretre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V; on the behalf of the FILO group. Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenstrom's macroglobulinemia. Ann Hematol. 2025 Jan;104(1):685-690. doi: 10.1007/s00277-024-06076-1. Epub 2024 Nov 5.
• Tomowiak C, Poulain S, Herbaux C, Perrot A, Mahe B, Morel P, Aurran T, Tournilhac O, Lepretre S, Assaad S, Villemagne B, Casasnovas O, Nollet D, Roos-Weil D, Chevret S, Leblond V. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood Adv. 2021 May 11;5(9):2438-2446. doi: 10.1182/bloodadvances.2020003895.

Drugs

Indications